570 related articles for article (PubMed ID: 26352219)
21. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars.
Peliçário Vargas B; Sari MHM; Ferreira LM
Anticancer Agents Med Chem; 2022; 22(14):2507-2516. PubMed ID: 35236272
[TBL] [Abstract][Full Text] [Related]
23. [Biosimilar drugs in oncology].
Levêque D
Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422
[TBL] [Abstract][Full Text] [Related]
24. SB3 (Ontruzant
Lamb YN
BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
[TBL] [Abstract][Full Text] [Related]
25. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
26. Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars.
Uifălean A; Ilieş M; Nicoară R; Rus LM; Hegheş SC; Iuga CA
Pharmaceutics; 2018 Sep; 10(4):. PubMed ID: 30257528
[TBL] [Abstract][Full Text] [Related]
27. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
28. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
Giuliani J; Bonetti A
Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
[TBL] [Abstract][Full Text] [Related]
29. [The development of biosimilars in oncology].
Jiang SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract][Full Text] [Related]
31. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
32. Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
AbdulHameed Saeed V; Mohammed NAK
Arch Razi Inst; 2023 Jun; 78(3):981-988. PubMed ID: 38028843
[TBL] [Abstract][Full Text] [Related]
33. Clinical evidence supporting the marketing authorization of biosimilars in Europe.
Allocati E; Bertele' V; Gerardi C; Garattini S; Banzi R
Eur J Clin Pharmacol; 2020 Apr; 76(4):557-566. PubMed ID: 31897530
[TBL] [Abstract][Full Text] [Related]
34. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
35. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
36. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
37. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
[TBL] [Abstract][Full Text] [Related]
38. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
[TBL] [Abstract][Full Text] [Related]
39. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
40. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
